Recent Company News

• 04:14 AM ET Feb 12, 2026
  

  StreetAccount Summary: EU stocks reaching new 52-week highs/lows (208 total)

• 06:15 AM ET Feb 07, 2026
  

  EPA announces new registration enabling Bayer to launch Strayax dicamba herbicide for 2026 season (€45.80, 0.00)

• 02:54 AM ET Feb 06, 2026
  

  StreetAccount Summary - European pre-market trading update

• 01:50 AM ET Feb 06, 2026
  

  European macro headlines:

• 12:23 PM ET Feb 05, 2026
  

  Bayer's discloses Asundexian Phase 3 study results demonstrating a 26% reduction in stroke (€44.82, 0.00)

• 04:36 PM ET Feb 03, 2026
  

  Corteva reports Q4 operating EPS $0.22 vs FactSet $0.22 [18 est, $0.19-0.33]

• 04:04 AM ET Feb 03, 2026
  

  Bayer AG's Nubeqa (darolutamide) receives third approval in China for men with advanced prostate cancer (€45.51, +0.50)

• 07:06 AM ET Jan 30, 2026
  

  EU's CHMP adopted a positive opinion recommending recommending a change to the terms of the marketing authorisation for Bayer's Kerendia (€43.96, -0.06)

• 03:35 AM ET Jan 29, 2026
  

  Alvotech reaches Eylea licensing and settlement agreement with Regeneron and Bayer ($5.29, 0.00)

• 07:36 AM ET Jan 27, 2026
  

  Bayer to present the main results from its Phase III study OCEANIC-STROKE of asundexian in secondary stroke prevention at the upcoming American Stroke Assn's ISC (€45.99, -0.38)